Cite

HARVARD Citation

    Hsu, A. et al. (2022). CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab. Leukemia & lymphoma. 63 (1), pp. 31-42. [Online]. 
  
Back to record